by | Dec 18, 2024 | Klechevsky, Eynav, Pathak, Amit, Sarker, Bapi
— Published Date: 12/19/2024
Value Proposition: New method for expanding T cells against individualized tumor-specific mutational antigens.
Technology Description
Researchers at Washington University in St. Louis have developed a device that enables high-throughput production of patient specific …
by | Oct 15, 2024 | Shea, Susan, Spinella, Philip, Thomas, Kimberly
— Value Proposition: Composition of matter that uses taurine to improve cold platelet storage shelf life and functionality.
Technology Description
Researchers at Washington University in St. Louis have developed a method to cold store platelets using taurine supplementation. There is a crucial ne…
by | Jul 18, 2024 | Kim, Brian
—
Value proposition: Novel approach to treat chronic itch through the intrathecal or intranasal delivery of JAK inhibitors.
Technology Description
Researchers at Washington University in St. Louis have developed a new method for treating chronic idiopathic pruritus (CIP) in both patients and m…
by | Oct 13, 2023 | Dodson, Karen, Ellebedy, Ali, Feldman, Mario, Hultgren, Scott, Pinkner, Jerome, Tamadonfar, Kevin, Timm, Morgan
— Technology Description
Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
by | Jun 28, 2022 | Klein, Robyn, Williams, Jessica
— Technology Description
Researchers in Prof. Robyn Klein’s laboratory have discovered that interferon lambda (IFN-λ) is a potential target for treating multiple sclerosis (MS), particularly secondary progressive MS (SPMS).
Most patients with MS present with relapsing remitting MS (RRM…